Bo Zhang, Yushan Jin, Lei Zhang, Hongshuang Wang* and Xiaohui Wang* Pages 4602 - 4609 ( 8 )
Pentamidine, an FDA-approved human drug for many protozoal infections, was initially synthesized in the late 1930s and first reported to be curative for parasitosis in the 1940s. After ninety years of sometimes quiet growth, pentamidine and its derivatives have gone far beyond antibacterial agents, including but not limited to the ligands of DNA minor groove, modulators of PPIs (protein-protein interactions) of the transmembrane domain 5 of lateral membrane protein 1, and the blockers of the SARS-CoV-2 3a channel. This mini-review highlights the development and applications of pentamidine and its analogs, aiming to provide insights for further developing pentamidine derivatives in the following decades.
Pentamidine, antimicrobial drug, DNA minor groove ligands, SARS-CoV-2, 3a channel, inhibitors of PPIs, amidine.